Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

In vivo selective inhibition of TRPC6 by antagonist BI 749327 ameliorates fibrosis and dysfunction in cardiac and renal disease.

Lin BL, Matera D, Doerner JF, Zheng N, Del Camino D, Mishra S, Bian H, Zeveleva S, Zhen X, Blair NT, Chong JA, Hessler DP, Bedja D, Zhu G, Muller GK, Ranek MJ, Pantages L, McFarland M, Netherton MR, Berry A, Wong D, Rast G, Qian HS, Weldon SM, Kuo JJ, Sauer A, Sarko C, Moran MM, Kass DA, Pullen SS.

Proc Natl Acad Sci U S A. 2019 May 14;116(20):10156-10161. doi: 10.1073/pnas.1815354116. Epub 2019 Apr 26.

PMID:
31028142
2.

Renal compartment-specific genetic variation analyses identify new pathways in chronic kidney disease.

Qiu C, Huang S, Park J, Park Y, Ko YA, Seasock MJ, Bryer JS, Xu XX, Song WC, Palmer M, Hill J, Guarnieri P, Hawkins J, Boustany-Kari CM, Pullen SS, Brown CD, Susztak K.

Nat Med. 2018 Nov;24(11):1721-1731. doi: 10.1038/s41591-018-0194-4. Epub 2018 Oct 1.

3.

Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.

Beckerman P, Bi-Karchin J, Park AS, Qiu C, Dummer PD, Soomro I, Boustany-Kari CM, Pullen SS, Miner JH, Hu CA, Rohacs T, Inoue K, Ishibe S, Saleem MA, Palmer MB, Cuervo AM, Kopp JB, Susztak K.

Nat Med. 2017 Apr;23(4):429-438. doi: 10.1038/nm.4287. Epub 2017 Feb 20.

4.

Urinary Exosomal miRNA Signature in Type II Diabetic Nephropathy Patients.

Delić D, Eisele C, Schmid R, Baum P, Wiech F, Gerl M, Zimdahl H, Pullen SS, Urquhart R.

PLoS One. 2016 Mar 1;11(3):e0150154. doi: 10.1371/journal.pone.0150154. eCollection 2016.

5.

A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat.

Boustany-Kari CM, Harrison PC, Chen H, Lincoln KA, Qian HS, Clifford H, Wang H, Zhang X, Gueneva-Boucheva K, Bosanac T, Wong D, Fryer RM, Richman JG, Sarko C, Pullen SS.

J Pharmacol Exp Ther. 2016 Mar;356(3):712-9. doi: 10.1124/jpet.115.230706. Epub 2016 Jan 4.

PMID:
26729306
6.

Discovery of potent, selective chymase inhibitors via fragment linking strategies.

Taylor SJ, Padyana AK, Abeywardane A, Liang S, Hao MH, De Lombaert S, Proudfoot J, Farmer BS 3rd, Li X, Collins B, Martin L, Albaugh DR, Hill-Drzewi M, Pullen SS, Takahashi H.

J Med Chem. 2013 Jun 13;56(11):4465-81. doi: 10.1021/jm400138z. Epub 2013 Jun 4.

PMID:
23659209
7.

Benzimidazolone as potent chymase inhibitor: modulation of reactive metabolite formation in the hydrophobic (P1) region.

Lo HY, Nemoto PA, Kim JM, Hao MH, Qian KC, Farrow NA, Albaugh DR, Fowler DM, Schneiderman RD, Michael August E, Martin L, Hill-Drzewi M, Pullen SS, Takahashi H, De Lombaert S.

Bioorg Med Chem Lett. 2011 Aug 1;21(15):4533-9. doi: 10.1016/j.bmcl.2011.05.126. Epub 2011 Jun 17.

PMID:
21733690
8.

5-Aminomethylbenzimidazoles as potent ITK antagonists.

Riether D, Zindell R, Kowalski JA, Cook BN, Bentzien J, Lombaert SD, Thomson D, Kugler SZ Jr, Skow D, Martin LS, Raymond EL, Khine HH, O'Shea K, Woska JR Jr, Jeanfavre D, Sellati R, Ralph KL, Ahlberg J, Labissiere G, Kashem MA, Pullen SS, Takahashi H.

Bioorg Med Chem Lett. 2009 Mar 15;19(6):1588-91. doi: 10.1016/j.bmcl.2009.02.012. Epub 2009 Feb 8.

PMID:
19246196
9.

Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.

Cook BN, Bentzien J, White A, Nemoto PA, Wang J, Man CC, Soleymanzadeh F, Khine HH, Kashem MA, Kugler SZ Jr, Wolak JP, Roth GP, De Lombaert S, Pullen SS, Takahashi H.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):773-7. doi: 10.1016/j.bmcl.2008.12.028. Epub 2008 Dec 10.

PMID:
19111460
10.

2-Aminobenzimidazoles as potent ITK antagonists: trans-stilbene-like moieties targeting the kinase specificity pocket.

Lo HY, Bentzien J, Fleck RW, Pullen SS, Khine HH, Woska JR Jr, Kugler SZ, Kashem MA, Takahashi H.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6218-21. doi: 10.1016/j.bmcl.2008.09.098. Epub 2008 Oct 2.

PMID:
18930400
11.

5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).

Winters MP, Robinson DJ, Khine HH, Pullen SS, Woska JR Jr, Raymond EL, Sellati R, Cywin CL, Snow RJ, Kashem MA, Wolak JP, King J, Kaplita PV, Liu LH, Farrell TM, DesJarlais R, Roth GP, Takahashi H, Moriarty KJ.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5541-4. doi: 10.1016/j.bmcl.2008.09.016. Epub 2008 Sep 7.

PMID:
18823779
12.

Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk).

Moriarty KJ, Takahashi H, Pullen SS, Khine HH, Sallati RH, Raymond EL, Woska JR Jr, Jeanfavre DD, Roth GP, Winters MP, Qiao L, Ryan D, DesJarlais R, Robinson D, Wilson M, Bobko M, Cook BN, Lo HY, Nemoto PA, Kashem MA, Wolak JP, White A, Magolda RL, Tomczuk B.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5545-9. doi: 10.1016/j.bmcl.2008.09.015. Epub 2008 Sep 7. Erratum in: Bioorg Med Chem Lett. 2009 Mar 15;19(6):1835.

PMID:
18819799
13.

Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead.

Moriarty KJ, Winters M, Qiao L, Ryan D, DesJarlis R, Robinson D, Cook BN, Kashem MA, Kaplita PV, Liu LH, Farrell TM, Khine HH, King J, Pullen SS, Roth GP, Magolda R, Takahashi H.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5537-40. doi: 10.1016/j.bmcl.2008.09.017. Epub 2008 Sep 7.

PMID:
18819794
14.

Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.

Snow RJ, Abeywardane A, Campbell S, Lord J, Kashem MA, Khine HH, King J, Kowalski JA, Pullen SS, Roma T, Roth GP, Sarko CR, Wilson NS, Winters MP, Wolak JP, Cywin CL.

Bioorg Med Chem Lett. 2007 Jul 1;17(13):3660-5. Epub 2007 Apr 25.

PMID:
17499505
15.

Three mechanistically distinct kinase assays compared: Measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors.

Kashem MA, Nelson RM, Yingling JD, Pullen SS, Prokopowicz AS 3rd, Jones JW, Wolak JP, Rogers GR, Morelock MM, Snow RJ, Homon CA, Jakes S.

J Biomol Screen. 2007 Feb;12(1):70-83. Epub 2006 Dec 8.

PMID:
17166826
16.

Signaling and protein associations of a cell permeable CD40 complex in B cells.

Zoog SJ, Papov VV, Pullen SS, Jakes S, Kehry MR.

Mol Immunol. 2004 Jan;40(10):681-94.

PMID:
14644094
17.

The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells.

Ahonen C, Manning E, Erickson LD, O'Connor B, Lind EF, Pullen SS, Kehry MR, Noelle RJ.

Nat Immunol. 2002 May;3(5):451-6. Epub 2002 Apr 22.

18.

Cellular responses to murine CD40 in a mouse B cell line may be TRAF dependent or independent.

Manning E, Pullen SS, Souza DJ, Kehry M, Noelle RJ.

Eur J Immunol. 2002 Jan;32(1):39-49.

19.

Structural and biochemical analysis of signal transduction by the TRAF family of adapter proteins.

McWhirter SM, Pullen SS, Werneburg BG, Labadia ME, Ingraham RH, Crute JJ, Kehry MR, Alber T.

Cold Spring Harb Symp Quant Biol. 1999;64:551-62. Review. No abstract available.

PMID:
11232332
20.

High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization.

Pullen SS, Labadia ME, Ingraham RH, McWhirter SM, Everdeen DS, Alber T, Crute JJ, Kehry MR.

Biochemistry. 1999 Aug 3;38(31):10168-77.

PMID:
10433725
21.

Crystallographic analysis of CD40 recognition and signaling by human TRAF2.

McWhirter SM, Pullen SS, Holton JM, Crute JJ, Kehry MR, Alber T.

Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8408-13.

23.

Recombinant IkappaB kinases alpha and beta are direct kinases of Ikappa Balpha.

Li J, Peet GW, Pullen SS, Schembri-King J, Warren TC, Marcu KB, Kehry MR, Barton R, Jakes S.

J Biol Chem. 1998 Nov 13;273(46):30736-41.

24.

Supplemental Content

Loading ...
Support Center